BACKGROUND: The purpose was to present the prevalence of all psychotic and bipolar (BP) disorders in a total general population (n=3563), which has been followed from 1947 to 1997. MATERIALS AND METHODS: Best-estimate consensus DSM-IV diagnoses, supported by data from interviews, case notes, registers and key-informants, were assessed. The period prevalence from 1947 to 1997 and the lifetime prevalence (LTP) in 1997, respectively, was calculated. RESULTS: The period prevalence per 100 was: 4.24 for any psychotic or BP disorder, 2.25 for non-affective psychotic (NAP) disorder, 0.76 for psychotic disorder related to a general medical condition (GMC), 0.62 for affective psychotic (AP) disorder and 0.59 for substance-induced psychotic (SIP) disorder. The LTP per 100 was: 2.82 for any psychotic or BP disorder, 1.38 for NAP disorder, 0.54 for psychotic disorder related to a GMC, 0.48 for SIP disorder and 0.42 for AP disorder. The specific diagnosis with the highest period prevalence 1.43 per 100 and LTP 0.84 per 100, respectively, was schizophrenia. The LTP of psychotic disorder related to a GMC, SIP disorder, schizophrenia and delusional disorder, respectively, was higher than in most recent community studies while the LTP of brief psychotic disorder, schizophreniform disorder and AP disorder, respectively, was lower. However, the findings were in approximate accord with the estimates in the Psychoses in Finland (PIF) Study 1. CONCLUSIONS: The findings suggest that psychotic disorders are common in the community, and should be considered a major public health concern.
BACKGROUND: The purpose was to present the prevalence of all psychotic and bipolar (BP) disorders in a total general population (n=3563), which has been followed from 1947 to 1997. MATERIALS AND METHODS: Best-estimate consensus DSM-IV diagnoses, supported by data from interviews, case notes, registers and key-informants, were assessed. The period prevalence from 1947 to 1997 and the lifetime prevalence (LTP) in 1997, respectively, was calculated. RESULTS: The period prevalence per 100 was: 4.24 for any psychotic or BP disorder, 2.25 for non-affective psychotic (NAP) disorder, 0.76 for psychotic disorder related to a general medical condition (GMC), 0.62 for affective psychotic (AP) disorder and 0.59 for substance-induced psychotic (SIP) disorder. The LTP per 100 was: 2.82 for any psychotic or BP disorder, 1.38 for NAP disorder, 0.54 for psychotic disorder related to a GMC, 0.48 for SIP disorder and 0.42 for AP disorder. The specific diagnosis with the highest period prevalence 1.43 per 100 and LTP 0.84 per 100, respectively, was schizophrenia. The LTP of psychotic disorder related to a GMC, SIP disorder, schizophrenia and delusional disorder, respectively, was higher than in most recent community studies while the LTP of brief psychotic disorder, schizophreniform disorder and AP disorder, respectively, was lower. However, the findings were in approximate accord with the estimates in the Psychoses in Finland (PIF) Study 1. CONCLUSIONS: The findings suggest that psychotic disorders are common in the community, and should be considered a major public health concern.
Authors: Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa Journal: Schizophr Res Date: 2018-02-03 Impact factor: 4.939
Authors: Robert J Fortuna; Laura Robinson; Tristram H Smith; Jon Meccarello; Beth Bullen; Kathryn Nobis; Philip W Davidson Journal: J Gen Intern Med Date: 2015-09-11 Impact factor: 5.128
Authors: E S Gouvea; V K Ota; C Noto; M L Santoro; L M Spindola; P N Moretti; C M Carvalho; G Xavier; A C Rios; J R Sato; M A F Hayashi; E Brietzke; A Gadelha; R A Bressan; Q Cordeiro; S I Belangero Journal: Transl Psychiatry Date: 2016-10-04 Impact factor: 6.222
Authors: Maria Stella Calafato; Johan H Thygesen; Siri Ranlund; Eirini Zartaloudi; Wiepke Cahn; Benedicto Crespo-Facorro; Álvaro Díez-Revuelta; Marta Di Forti; Mei-Hua Hall; Conrad Iyegbe; Assen Jablensky; Rene Kahn; Luba Kalaydjieva; Eugenia Kravariti; Kuang Lin; Colm McDonald; Andrew M McIntosh; Andrew McQuillin; Marco Picchioni; Dan Rujescu; Madiha Shaikh; Timothea Toulopoulou; Jim Van Os; Evangelos Vassos; Muriel Walshe; John Powell; Cathryn M Lewis; Robin M Murray; Elvira Bramon Journal: Br J Psychiatry Date: 2018-09 Impact factor: 9.319
Authors: Eben Holderness; Nicholas Miller; Philip Cawkwell; Kirsten Bolton; Marie Meteer; James Pustejovsky; Mei-Hua Hall Journal: J Biomed Semantics Date: 2019-10-31
Authors: Elvira Bramon; Matti Pirinen; Amy Strange; Kuang Lin; Colin Freeman; Céline Bellenguez; Zhan Su; Gavin Band; Richard Pearson; Damjan Vukcevic; Cordelia Langford; Panos Deloukas; Sarah Hunt; Emma Gray; Serge Dronov; Simon C Potter; Avazeh Tashakkori-Ghanbaria; Sarah Edkins; Suzannah J Bumpstead; Maria J Arranz; Steven Bakker; Stephan Bender; Richard Bruggeman; Wiepke Cahn; David Chandler; David A Collier; Benedicto Crespo-Facorro; Paola Dazzan; Lieuwe de Haan; Marta Di Forti; Milan Dragović; Ina Giegling; Jeremy Hall; Conrad Iyegbe; Assen Jablensky; René S Kahn; Luba Kalaydjieva; Eugenia Kravariti; Stephen Lawrie; Don H Linszen; Ignacio Mata; Colm McDonald; Andrew McIntosh; Inez Myin-Germeys; Roel A Ophoff; Carmine M Pariante; Tiina Paunio; Marco Picchioni; Stephan Ripke; Dan Rujescu; Heinrich Sauer; Madiha Shaikh; Jessika Sussmann; Jaana Suvisaari; Sarah Tosato; Timothea Toulopoulou; Jim Van Os; Muriel Walshe; Matthias Weisbrod; Heather Whalley; Durk Wiersma; Jenefer M Blackwell; Matthew A Brown; Juan P Casas; Aiden Corvin; Audrey Duncanson; Janusz A Z Jankowski; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Nicholas W Wood; Ines Barroso; Leena Peltonen; Cathryn M Lewis; Robin M Murray; Peter Donnelly; John Powell; Chris C A Spencer Journal: Biol Psychiatry Date: 2013-07-17 Impact factor: 13.382